Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Latest Information Update: 30 Oct 2024
Price :
$35 *
At a glance
- Drugs VC 004 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
- 30 Oct 2024 New trial record